DEPOSIT AGREEMENT by and among MEREO BIOPHARMA GROUP PLC and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [DATE], 2018Deposit Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of [DATE], 2018, by and among (i) Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
THIS CONTRACT OF EMPLOYMENT dated 26 February 2018 is made BETWEEN:Mereo Biopharma Group PLC • March 23rd, 2018 • Pharmaceutical preparations • England
This Contract sets out the terms and conditions of your employment with the Company at the date of this Contract and supersedes all previous arrangements or agreements whether oral or in writing between you and the Company in relation to the matters dealt with in it.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. SUBLICENSE AGREEMENTSublicense Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This SUBLICENSE AGREEMENT (this “Agreement”), effective as of July 29, 2015 (the “Effective Date”), is by and between MEREO BIOPHARMA 3 LIMITED, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of MEREO BIOPHARMA GROUP LIMITED, a company incorporated in England and Wales (“Mereo”), and NOVARTIS PHARMA AG, a Swiss company (“Novartis”).
EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AND OPTION AGREEMENT (the “Agreement”) is made and entered into effective as of 28 October 2017 (the “Effective Date”) by and between ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden (“AstraZeneca”), and MEREO BIOPHARMA 4 LIMITED, a company incorporated in England and Wales under no. 11029583 with its registered office at 4th Floor, One, Cavendish Place, London, W1G 0QF (“Mereo”). AstraZeneca and Mereo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BCT197 ASSET PURCHASE AGREEMENT by and between...Bct197 Asset Purchase Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BCT197 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 1 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BGS649 ASSET PURCHASE AGREEMENT by and between...Bgs649 Asset Purchase Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BGS649 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 2 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
MEREO BIOPHARMA GROUP PLC AND JOHN RICHARD AND JOHN RICHARD & ASSOCIATES, LLC CONSULTANCY AGREEMENTConsultancy Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations
This consultancy agreement (this “Agreement”) has been entered into this 1st day of February 2018 and shall replace the agreement between the Parties dated 17 January 2018.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BPS804 ASSET PURCHASE AGREEMENT by and between...Bps804 Asset Purchase Agreement • March 23rd, 2018 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BPS804 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 3 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
Mereo BioPharma Group plc and Deed of IndemnityMereo Biopharma Group PLC • March 23rd, 2018 • Pharmaceutical preparations • England
